April 22, 2021 | Featured
London, UK and Seoul, South Korea. 22nd April 2021.
Intract Pharma (Intract), an oral biologics delivery technology company, today announces entry into a research collaboration agreement with NIBEC (South Korea) to evaluate Intract’s proprietary oral biologics delivery platform technologies, Soteria® and Phloral®, to develop an oral, dual-targeting peptide therapeutic for local gut-restricted treatment of ulcerative colitis.
Under the agreement, Intract will optimise the peptide’s intestinal stability and tissue uptake and will develop oral formulations for in-vivo pre-clinical testing. Upon completion of the study, NIBEC will have an option to negotiate an exclusive worldwide license to Intract technologies for delivery of NIBEC’s peptide therapeutic.
Commenting on the collaboration, Bill Lindsay, CEO of Intract said “Intract is very pleased to enter this collaboration which will draw on Intract’s expertise in development of oral biologics to seek to create a new and exciting treatment for IBD”
Dr Chong Pyung Chung, CEO of NIBEC said “We are very delighted to increase the delivery efficacy of peptide therapeutic (NIPEP-IBD) as oral formulation by collaboration with Intract Pharma. We are looking forward to demonstrating proof of concept of oral formation of NIPEP-IBD and entering further human study.”
About Intract Pharma
Intract Pharma is a company which specializes in oral drug delivery, developing state-of-the-art formulation technologies and unique gastrointestinal models to develop advanced new therapeutics. Since its inception, Intract has pursued innovation in oral drug delivery as a means to improve on current therapies, making them safer and more effective for patients. The drug delivery technologies Phloral® for precise colonic drug delivery, and Soteria® for delivery of biotherapeutics to gastrointestinal tissue, are available for license exclusively from Intract Pharma. For more information visit www.intractpharma.com
NIBEC is established as a spin-off venture from Seoul National University, South Korea at 2004 and listed in Korean Stock Market (KOSDAQ) at 2011. The company’s main technology is based on target-oriented peptide therapeutic discovery (TOPscovery) platform for drug discovery and delivery. The company’s focus of therapeutic area are inflammatory diseases (IBD, Ulcerative colitis, NASH, Fibrosis), oncology with specialized peptide drug formulation and new mode of action. In addition, NIBEC has specialized target tissue/cell penetrating peptide delivery platform to deliver protein/antibody/siRNA into the target tissue such as cancer. For more information is available at company website at www.nibec.co.kr.
Copyright © 2018 Intract Pharma
A site by: Web Design London